Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations.

Demystifying physiologically based... | Gates Open Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://gatesopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'gates'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content Gates Open Research file_upload Submit via VeriXiv search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit via VeriXiv My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Publication Charges Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In Submit via VeriXiv { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://gatesopenresearch.org/articles/7-128" }, "headline": "Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed...", "datePublished": "2023-10-26T08:25:37", "dateModified": "2023-10-26T08:25:37", "author": [ { "@type": "Person", "name": "Jolien Freriksen" }, { "@type": "Person", "name": "Joyce van der Heijden" }, { "@type": "Person", "name": "Marika de Hoop-Sommen" }, { "@type": "Person", "name": "Trevor Johnson" }, { "@type": "Person", "name": "Karen R Yeo" }, { "@type": "Person", "name": "Essam Kerwash" }, { "@type": "Person", "name": "Susan Cole" }, { "@type": "Person", "name": "Janet Nooney" }, { "@type": "Person", "name": "Rick Greupink" }, { "@type": "Person", "name": "Ping Zhao" }, { "@type": "Person", "name": "Saskia de Wildt" } ], "publisher": { "@type": "Organization", "name": "Gates Open Research", "logo": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 600, "width": 47 } }, "image": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 1200, "width": 94 }, "description": "Physiologically based pharmacokinetic (PBPK) models represent computational technology to characterize drug behavior within the context of detailed human physiology. Today, PBPK is routinely used in drug development and regulatory approval to support decisions on how a medicine can be used under certain clinical conditions. As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women. To facilitate broader applications of PBPK for these populations, we joined force and organized five hands-on workshops primarily to non-modelers on the principles of PBPK and its potential applications in pediatric and obstetric pharmacology in 2021 and 2022. In this open letter, we report learning objectives and content of such workshops and to highlight the significant value of these educational efforts." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://gatesopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://gatesopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://gatesopenresearch.org/articles/7-128/v1", "name": "Demystifying physiologically based pharmacokinetic modelling among..." } } ] } Home Browse Demystifying physiologically based pharmacokinetic modelling among... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Freriksen J, Heijden Jvd, de Hoop-Sommen M et al. Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.12688/gatesopenres.14896.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Open Letter Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] Jolien Freriksen 1 , Joyce van der Heijden 1 , Marika de Hoop-Sommen 1 , [...] Trevor Johnson 2 , Karen R Yeo 2 , Essam Kerwash https://orcid.org/0000-0003-4368-8565 3 , Susan Cole 3 , Janet Nooney 2 , Rick Greupink 1 , Ping Zhao https://orcid.org/0009-0009-6335-3464 4 , Saskia de Wildt 1,5 Jolien Freriksen 1 , Joyce van der Heijden 1 , [...] Marika de Hoop-Sommen 1 , Trevor Johnson 2 , Karen R Yeo 2 , Essam Kerwash https://orcid.org/0000-0003-4368-8565 3 , Susan Cole 3 , Janet Nooney 2 , Rick Greupink 1 , Ping Zhao https://orcid.org/0009-0009-6335-3464 4 , Saskia de Wildt 1,5 PUBLISHED 26 Oct 2023 Author details Author details 1 Radboud University, Nijmegen, Gelderland, The Netherlands 2 Certara UK Limited, Sheffield, UK 3 Medicines and Healthcare Products Regulatory Agency, London, UK 4 Bill & Melinda Gates Foundation, Seattle, Washington, USA 5 Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands Jolien Freriksen Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing Joyce van der Heijden Roles: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Marika de Hoop-Sommen Roles: Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Trevor Johnson Roles: Data Curation, Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation, Writing – Review & Editing Karen R Yeo Roles: Data Curation, Investigation, Methodology, Resources, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Essam Kerwash Roles: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Susan Cole Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Janet Nooney Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Rick Greupink Roles: Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Ping Zhao Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Saskia de Wildt Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Physiologically based pharmacokinetic (PBPK) models represent computational technology to characterize drug behavior within the context of detailed human physiology. Today, PBPK is routinely used in drug development and regulatory approval to support decisions on how a medicine can be used under certain clinical conditions. As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women. To facilitate broader applications of PBPK for these populations, we joined force and organized five hands-on workshops primarily to non-modelers on the principles of PBPK and its potential applications in pediatric and obstetric pharmacology in 2021 and 2022. In this open letter, we report learning objectives and content of such workshops and to highlight the significant value of these educational efforts. READ ALL READ LESS Keywords Dosing, Under-served Populations, Model-informed Drug Development, Pediatrics, Pharmacokinetics, Pregnancy Corresponding Author(s) Jolien Freriksen ( [email protected] ) Ping Zhao ( [email protected] ) Close Corresponding authors: Jolien Freriksen, Ping Zhao Competing interests: T.N.J. and K.R.Y. are employees of Certara UK Limited (Simcyp Division). The authors declared no competing interests for this work. All other authors declare that they have no conflict of interest. Grant information: This work is supported by the Gates Foundation (INV-001822, INV-009383, and INV-040110). Copyright: © 2023 Freriksen J et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Freriksen J, Heijden Jvd, de Hoop-Sommen M et al. Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.12688/gatesopenres.14896.1 ) First published: 26 Oct 2023, 7 :128 ( https://doi.org/10.12688/gatesopenres.14896.1 ) Latest published: 26 Oct 2023, 7 :128 ( https://doi.org/10.12688/gatesopenres.14896.1 ) Disclaimer The views expressed in this article are those of the author(s). Publication in Gates Open Research does not imply endorsement by the Bill & Melinda Gates Foundation. The views may not be understood or quoted as being made on behalf of or reflecting the position of the Medicines and Healthcare products Regulatory Agency, UK. Ethics statement As it is not a medical/health research, no otherwise sensitive information was collected, participation was voluntarily and data were processed anonymously, explicit written informed consent was not sought. Value of physiologically based pharmacokinetic modeling for under-served populations There is a general lack of on-label drug dosing information for pediatric patients, pregnant and lactating women 1 , 2 . Historically, these populations have hardly been evaluated in clinical programs during the development of drug products. Even when clinical studies are conducted, the generalizability of such studies can be limited because the effect of relevant age and/or pregnancy-related physiological and anatomical variations can significantly complicate a drug’s pharmacology in a specific subgroup of these populations, calling for different dosage adjustments in different subgroups. To this end, computational tools such as physiologically based pharmacokinetic (PBPK) modeling which characterize the physiological changes can be used to support dosing decisions 3 – 5 . A PBPK model consists of several compartments representing organs and tissues. Maturational effects of physiology can be described using (gestational) age-dependent equations. This allows the creation of a set of virtual subjects, each representing anatomical and physiological characteristics of pediatric subjects or pregnant and lactating women at a specific developmental stage (the system model). In parallel, one can compile drug-dependent parameters to construct a drug model, and couple it with the system model through relevant physiological processes concerning the absorption and disposition of the drug. A user-defined virtual trial then can be conducted to simulate pharmacokinetic (PK) characteristics in a specific virtual subject or sub-population. Such PK information can then form the basis for dosing decisions 6 . In the last two decades, advancements in computation and pharmacological sciences fueled the industrialization of PBPK. Today, PBPK is a platform technology used routinely by drug developers and regulatory agencies to inform dosing recommendations for a wide range of applications 7 . Interest in PBPK modeling to predict PK in pediatric and pregnant subjects has increased dramatically over the past few years 6 , 8 . Of all regulatory submissions involving PBPK modeling received by the US Food and Drug Administration (FDA) in 2018 – 2019, 9% were related to pediatric population 7 . Application of pediatric PBPK models also increased in clinical and research settings, for both biologics and small molecules 9 . While in silico PBPK modeling is generally conducted to inform clinical trial design in pediatric and pregnant populations, it can also be applied in the post marketing stage to inform drug dosing 10 . Demystifying PBPK among non-modelers towards broader application in under-served populations PBPK is ideal to investigate and predict effects of dynamic physiological changes on a drug’s pharmacology. Although the FDA reported emerging use of PBPK in pediatrics, no application was recorded to inform drug dosing in pregnant and lactating women 7 . This gap can be attributed to the low confidence in PBPK for these intended uses, and/or the lack of understanding of today’s PBPK as a platform technology by broader medical communities. While the former can be continuously improved through increased PBPK research in the space of pediatric and obstetric pharmacology 6 , 8 , the latter requires introduction of PBPK to stakeholders who have little or no experience in pharmacology modeling. As such, we joined force and conducted five workshops in 2021 and 2022 primarily targeting these non-modeler audiences ( Table 1 ). Table 1. Five PBPK modeling workshops held in 2021 – 2022. a Radboud Summer School of 2021 also included exercises related to applying PBPK modeling to evaluate in vitro-to-in vivo extrapolation and drug-drug interactions in healthy subjects. b MHRA workshop aimed at those primarily interested in PK changes in pregnancy, rather than PBPK modeling specifically. (Supplemental file 1) Workshop Date, location and duration Attendees Populations discussed Number (% total) attendees participated in survey before the workshop Number (% total) attendees participated in survey after the workshop Part of the Radboud Summer School “Introduction to Pharmacokinetic and Pharmacodynamic Analysis” July 2021 Online Half day 26 delegates a (global) 5 tutors Pediatric and pregnant population 22 (85%) 12 (46%) Pre-congress course of the 19th European Society for Developmental Perinatal and Paediatric Pharmacology (ESDPPP) meeting June 2022 In-person Liverpool (UK) One day 37 delegates (mostly European) 11 tutors Pediatric and pregnant population 18 (49%) 9 (24%) Part of the Radboud Summer School “Introduction to Pharmacokinetic and Pharmacodynamic Analysis” July 2022 Online Half day 29 delegates a (global) 5 tutors Pediatric and pregnant population 28 (97%) 21 (72%) Satellite Session of the American Society for Clinical Pharmacology & Therapeutics (ASCPT) meeting September 2022 Online One day 45 delegates (global) 14 tutors Pediatric and pregnant population 33 (73%) 12 (27%) Medicines and Healthcare products Regulatory Agency (MHRA) workshop October 2022 In-person London (UK) One day + two (1hr) online pre-event sessions 32 delegates b (mostly UK) 7 tutors Pregnant population Not applicable as all feedback was collected after the workshop 20 (63% These workshops target clinicians, pharmacists, academic researchers and scientists from non-governmental organizations, ranging from the (PhD) student to senior fellows, as well as clinical assessors from regulatory agencies, with an interest in pediatrics and/or obstetrics pharmacology. Recruitment of participants were by targeted advertising and selection for MHRA workshop, and through announcement by Radboud Summer School, European Society for Developmental Perinatal and Paediatric Pharmacology (ESDPPP), and American Society for Clinical Pharmacology & Therapeutics (ASCPT). No inclusion/exclusion criterion was specified. No prior knowledge of PBPK modeling and accessibility to PBPK modeling software was required for Radboud Summer School, ESDPPP, and ASCPT events. All workshops shared similar features by including theoretical and hands-on sessions. The theoretical sessions were designed to (a) Disseminate the basics of PK and PBPK modeling. (b) Demonstrate the utility and impact of PBPK modeling in drug development and clinical practice. (c) Raise awareness of the impact of pregnancy and age-related changes on drug disposition. (d) Discuss key regulatory and clinical considerations when applying these models to inform drug dosing. The hands-on sessions employed a PBPK platform technology (Simcyp ® v21, Certara UK Limited, Simcyp Division, Sheffield, UK) to help attendees to (a) Become familiar with basics of PK and PBPK modeling. (b) Visualize the impact of anatomical and physiological changes on drug disposition. (c) Understand the implications of dose modification in children and pregnant women. Presentations of theoretical sessions were tailored according to the specific audience in a particular workshop and hands-on sessions were optimized with clinical cases that are generally familiar to the audience. The hands-on sessions were led by tutors in small groups each including 5 to 8 participants. Attendees accessed the Simcyp software via Amazon WorkSpaces. A mix of tutors from academia, industry or regulatory agencies enabled diverse discussions within each group. The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® ( https://www.simulations-plus.com/software/gastroplus/ ) and PKSim ® /Mobi ® ( https://www.open-systems-pharmacology.org/ ). A hands-on exercise was followed by a plenary session, in which results and perspectives by each group were shared with other groups to stimulate interactive discussions. In one case study of a typical workshop (e.g., ESDPPP), delegates first simulated PK of anti-HIV drug efavirenz after a typical dose in the adult population, followed by simulating different doses in the pediatric population according to different pediatric dosing guidelines (e.g., those from US Food and Drug Administration and World Health Organization). The groups then explored the impact of either ethnicity, a weekends-off treatment regimen, or varying assumptions on CYP2B6 ontogeny on efavirenz pharmacokinetics. Results were presented in the plenary, and delegates reported their findings and related real life clinical experiences to the simulation results. Final agendas including speakers, presentations, and hands-on case studies for these five workshops can be found in Supplementary File 1. Effectiveness of our workshops To understand the impact of our workshops, we conducted online surveys before and after the workshops (Supplementary file 2). Because the surveys are voluntary, not all participants responded ( Table 1 ). It was more challenging to obtain complete feedback after the workshop (for example, 36–75% of original responders before each workshop responded to the same question after the workshop at Radboud Summer School, ESDPPP and ASCPT events, Table 1 ), which limits the assessment of the impact of the workshop on changing attendees’ perspectives. As such, caution should be made when interpreting the survey results, especially when using percentage of responders to evaluate change in perspectives before and after the workshops. Some general findings from the surveys were: - The majority of responders across all five workshops were considered ‘non-modelers’ because they were not familiar with PBPK (Figures S4–S6, S23, Supplementary file 2). For Radboud, ESDPPP, and ASCPT workshops, many of the respondents were PhD students, followed by postdoctoral researchers and pharmacists, mostly working in the field of pediatrics. Most delegates had only heard and read about PBPK modeling prior to the workshop, did not read PBPK modeling papers frequently, and had the impression that PBPK studies are difficult to interpret. Participants at the MHRA workshop were mostly pharmacists or clinicians working in obstetrics, and none of the responders were confident in PBPK before the workshop. - The workshops appeared to be effective in leveling the ground for attendees to (i) understand state of science and technology and (ii) confidently apply PBPK. When asked ‘do you have sufficient knowledge and skills at this moment to conduct PBPK model simulations?’, most of the responders answered no before the workshops, yet they felt more capable of doing so after the workshop (Figure S7 of supplemental file 2). There was an increased percentage of responders after the workshop considering that ‘possessing mathematical and programming skills’ (Figure S10, supplemental file 2) is not necessarily essential. Similarly, responders at MHRA workshop tended to feel more confident in PBPK after the event (Figure S23–24, Supplemental file 2). The increased confidence and updated perspectives in attendees can be attributed to easy access to PBPK as a technology platform during the workshop, instead of modeling in the form of differential equations. With technology at hand, attendees can explore various modules constructed within the PBPK platform to visualize relevant physiology changes and pharmacological processes, execute simulations, and discuss simulation results within 30–45 minutes of a hands-on session. The experience of efficiently applying PBPK to answer clinical questions helped attendees to have updated views of PBPK. - The attendees appeared to appreciate the value of PBPK in optimizing medicine use in under-served populations. For example, responders’ answer to the question 'are we at the point of using PBPK model output to inform drug labelling' tended to transition from being split to being confident that the field is ready to apply PBPK output to inform drug labels (Figure S15, Supplemental file 2). Responders also acknowledged the capability of PBPK to simulate drug exposure in fetuses upon maternal administration, as well as drug exposure in preterm and term neonates after the workshops (Figure S15, Supplemental file 2). - All participants indicated the practical examples on dose adjustments with hands-on modeling as the most useful aspects. Many were interested in simulating dosing scenarios for specific drugs in tailored virtual patient populations, fostering follow-up discussions on research collaborations. - Clinically oriented users asked for a simpler interface for the PBPK modeling software and expressed an interest in more real-world examples, particularly related to the top 10 frequently used medicines in clinical practice. Whilst some expressed the desire to have access to more user-friendly dosing tools based on contemporary PBPK technology, others however indicated that they still wanted to understand the science behind the software. Final thoughts An adequate understanding of the concept and the state-of-the-technology of PBPK by healthcare providers is a critical step towards successful application of the tool to optimize pharmacotherapy in specific patient populations. Through these workshops, we effectively raised awareness of the relevance of PBPK in the context of clinical care, which reduces the barrier to implement PBPK modeling in informing drug dosing in children and pregnant women. We continue to collaborate in this space. Data availability Figshare. Supplemental files for "Demystifying Physiologically Based Pharmacokinetic Modeling among Non-Modelers towards Model-informed Medicine Use in Under-served Populations" (Submitted to Gates Open Research). DOI: 10.6084/m9.figshare.24153456 This project contains the following underlying data: Supplemental file 1 (Workshop agendas) Supplemental file 2 (survey results) Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Faculty Opinions recommended References 1. Schrier L, Hadjipanayis A, Stiris T, et al. : Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020; 179 (5): 839–47. PubMed Abstract | Publisher Full Text 2. Wisner KL, Stika CS, Watson K: Pregnant women are still therapeutic orphans. World Psychiatry. 2020; 19 (3): 329–30. PubMed Abstract | Publisher Full Text | Free Full Text 3. Perry C, Davis G, Conner TM, et al. : Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview. Curr Pharmacol Rep. 2020; 6 (3): 71–84. PubMed Abstract | Publisher Full Text | Free Full Text 4. Koren G, Pariente G: Pregnancy- Associated Changes in Pharmacokinetics and their Clinical Implications. Pharm Res. 2018; 35 (3): 61. PubMed Abstract | Publisher Full Text 5. Kearns GL, Abdel-Rahman SM, Alander SW, et al. : Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003; 349 (12): 1157–67. PubMed Abstract | Publisher Full Text 6. Verscheijden LFM, Koenderink JB, Johnson TN, et al. : Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Pharmacol Ther. 2020; 211 : 107541. PubMed Abstract | Publisher Full Text 7. Zhang X, Yang Y, Grimstein M, et al. : Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology. J Clin Pharmacol. 2020; 60 Suppl 1 : S160–S78. PubMed Abstract | Publisher Full Text 8. Chaphekar N, Dodeja P, Shaik IH, et al. : Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models. Front Pediatr. 2021; 9 : 733823. PubMed Abstract | Publisher Full Text | Free Full Text 9. Johnson TN, Small BG, Rowland Yeo K: Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations. CPT Pharmacometrics Syst Pharmacol. 2022; 11 (3): 373–83. PubMed Abstract | Publisher Full Text | Free Full Text 10. Freriksen JJM, van der Heijden JEM, de Hoop-Sommen MA, et al. : Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population. Paediatr Drugs. 2023; 25 (1): 5–11. PubMed Abstract | Publisher Full Text | Free Full Text Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 26 Oct 2023 ADD YOUR COMMENT Comment Author details Author details 1 Radboud University, Nijmegen, Gelderland, The Netherlands 2 Certara UK Limited, Sheffield, UK 3 Medicines and Healthcare Products Regulatory Agency, London, UK 4 Bill & Melinda Gates Foundation, Seattle, Washington, USA 5 Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands Jolien Freriksen Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing Joyce van der Heijden Roles: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Marika de Hoop-Sommen Roles: Data Curation, Formal Analysis, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Trevor Johnson Roles: Data Curation, Formal Analysis, Investigation, Methodology, Software, Writing – Original Draft Preparation, Writing – Review & Editing Karen R Yeo Roles: Data Curation, Investigation, Methodology, Resources, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Essam Kerwash Roles: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Susan Cole Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Janet Nooney Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Rick Greupink Roles: Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing Ping Zhao Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Saskia de Wildt Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests T.N.J. and K.R.Y. are employees of Certara UK Limited (Simcyp Division). The authors declared no competing interests for this work. All other authors declare that they have no conflict of interest. Grant information This work is supported by the Gates Foundation (INV-001822, INV-009383, and INV-040110). Article Versions (1) version 1 Published: 26 Oct 2023, 7:128 https://doi.org/10.12688/gatesopenres.14896.1 Copyright © 2023 Freriksen J et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads Gates Open Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Freriksen J, Heijden Jvd, de Hoop-Sommen M et al. Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.12688/gatesopenres.14896.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 26 Oct 2023 Views 0 Cite How to cite this report: Brooks KM. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36314 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36314 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 22 Jul 2024 Kristina M. Brooks , University of Colorado Anschutz Medical Campus, Aurora, USA Approved VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r36314 Freriksen et al. report on their experiences with providing workshops focused on educating non-modelers on the principles and potential applications of PBPK, with a more specific focus on pediatric, pregnant, and lactating populations. These educational initiatives are important for helping ... Continue reading READ ALL Freriksen et al. report on their experiences with providing workshops focused on educating non-modelers on the principles and potential applications of PBPK, with a more specific focus on pediatric, pregnant, and lactating populations. These educational initiatives are important for helping demonstrate the utility of this modeling approach to clinicians and researchers. General feedback from attendees appeared to confirm that these workshops did help “demystify” attendees’ understanding and ability to use/apply PBPK, and general findings from these trainings are helpful as a starting point for figuring out how to educate people on a larger scale. Please consider the following suggestions: Pg. 4, Table 1: consider providing a breakdown of the amount of time spent listening to didactic sessions vs. hands-on learning activities alongside the total duration of the workshops Pg. 4: The statement on “The technological requirement of a proprietary software…” felt a bit out of place and it did feel like some brief commentary on this aspect could also be helpful for readers. I would consider pulling this out into a separate paragraph/subheading on the ability to apply this to other software, but I do think explicitly noting open-source options and some of the pros/cons with this approach would be helpful if the authors are familiar with these other programs. Cost and ability to access software seem like important points to consider in addition to educating non-modelers in this space to ensure that these programs are used after the training. Pg. 5: There is a statement on “We continue to collaborate in this space.” However, I do think some high-level commentary on future directions and ways to potentially increase access would be helpful to give readers a sense of how this educational space will continue to evolve. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Clinical pharmacology, infectious diseases, pediatrics, pregnancy I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Brooks KM. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36314 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36314 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Kammala AK. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36765 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36765 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 19 Jul 2024 Ananth Kumar Kammala , The University of Texas Medical Branch at Galveston, Texas, USA Approved VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r36765 The manuscript, “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in underserved populations,” highlights the success of workshops designed to demystify physiologically based pharmacokinetic (PBPK) modeling for non-modelers. These workshops have effectively raised awareness and understanding among ... Continue reading READ ALL The manuscript, “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in underserved populations,” highlights the success of workshops designed to demystify physiologically based pharmacokinetic (PBPK) modeling for non-modelers. These workshops have effectively raised awareness and understanding among clinicians, pharmacists, and academic researchers about using PBPK to optimize drug dosing in underserved populations. The workshops engaged diverse participants, including PhD students, postdoctoral researchers, pharmacists, and clinical assessors from regulatory agencies. This wide range of attendees indicates the broad relevance and applicability of PBPK modeling in different fields. Although it has several advantages but there are few limitations of the manuscript to be addressed. The workshops relied on the proprietary software Simcyp®, which may not be accessible to all scientists. Although the manuscript suggests similar workshops could be conducted using other PBPK software platforms, such as GastroPlus® and PKSim®, the lack of direct experience with these alternatives is a limitation. The manuscript notes that interpreting survey results, particularly when comparing percentages to absolute numbers, can be challenging. This complexity may introduce bias in understanding the true impact of the workshops. By addressing these strengths and limitations, the manuscript provides a comprehensive overview of the value and challenges of using PBPK modeling to inform drug dosing in underserved populations. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Reproductive pharmacology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Kammala AK. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36765 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36765 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Maharaj A. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36766 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36766 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 19 Jul 2024 Anil Maharaj , University of British Columbia, Vancouver, Canada Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r36766 The submitted open letter summarizes 5 educational workshops on fostering an understanding of PBPK modeling to non-modelers and provides an analysis of feedback received from attendees. As PBPK modeling is commonly inferred to be an inherently complex process, the submitted ... Continue reading READ ALL The submitted open letter summarizes 5 educational workshops on fostering an understanding of PBPK modeling to non-modelers and provides an analysis of feedback received from attendees. As PBPK modeling is commonly inferred to be an inherently complex process, the submitted letter, which details how educational workshops can be used to bridge the knowledge gap among non-modelers, is of contemporary interest. A key strength of this letter is the collection and analysis of quantitative survey data from workshop attendees as it serves to substantiate assertions/positions discussed by the authors. The following comments are focused on improving the clarity of the submitted letter: 1. Abstract: “As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women.” Logical flaw - The opening sentences of the abstract do not provide an appropriate context/rationale as to why PBPK modeling is suitable for examining PK in underserved populations. 2. “To this end, computational tools such as physiologically based pharmacokinetic (PBPK) modeling which characterize the physiological changes can be used to support dosing decisions (3–5)” References (particularly ref 4 and 5) do not discuss the use of PBPK modeling to support drug dosing decisions. 3. “In parallel, one can compile drug-dependent parameters to construct a drug model, and couple it with the system model through relevant physiological processes concerning the absorption and dis- position of the drug.” Confusing sentence – unclear as to what is the output from combining drug- and system-specific parameters. Consider revising to indicate that combining drug- and system-specific parameters allows models to generate PK estimates that are developmentally specific. 4. Suggest defining the acronym MHRA in the body of the letter. 5. Suggest indicating how many (of the 5) workshops were online and how many were in-person within the body of the letter. 6. Why were MHRA survey results not integrated with the rest of the workshops in supplementary document 2? Were the survey questions for this workshop unique or different? 7. Consider including dialogue on how future workshops could be improved (or separating the ‘Effectiveness of our workshops’ section between strengths and areas for improvement). 8. “The increased confidence and updated perspectives in attendees can be attributed to easy access to PBPK as a technology platform during the workshop, instead of modeling in the form of differential equations.” Do survey results directly support this statement? If so, please include dialogue that links this proposition to quantitative results from the survey. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Pharmacokinetic modeling, pediatrics, pregnancy, and lactation. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Maharaj A. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36766 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36766 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Guo-Fu L. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36760 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36760 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 19 Jul 2024 Li Guo-Fu , China Pharmaceutical University,, Nanjing, China; Subei People's Hospital, Yangzhou, China Approved VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r36760 I find this open letter written by renowned and experienced experts in the field of PBPK modeling to be both interesting and informative. I have one suggestion: should the authors emphasize the best practice strategy in the use of PBPK ... Continue reading READ ALL I find this open letter written by renowned and experienced experts in the field of PBPK modeling to be both interesting and informative. I have one suggestion: should the authors emphasize the best practice strategy in the use of PBPK modeling to address specific medicine use questions in underserved populations? Highlighting the best practice, particularly regarding the differing levels of quantification or verification of PBPK, could enhance the confidence of non-modeler attendees in using their PBPK models to address their intended questions. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Physiologically-based pharmacokinetic modeling; clinical pharmacology; clinical pharmacy; biostatistics I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Guo-Fu L. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36760 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36760 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Amaeze OU. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36318 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36318 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 19 Jul 2024 Ogochukwu Ukamaka Amaeze , University of Washington, Washington, USA; Clinical Pharmacy and Biopharmacy, University of Lagos, Yaba, Federal Capital Territory, Nigeria Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r36318 The paper “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations” outlines the details and outcomes of five workshops designed for non-modelers. These workshops aimed to impart knowledge of the science and technology behind PBPK ... Continue reading READ ALL The paper “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations” outlines the details and outcomes of five workshops designed for non-modelers. These workshops aimed to impart knowledge of the science and technology behind PBPK modeling and foster confidence in its application to enhance drug therapy in underserved populations, including children and pregnant women. The paper highlights the benefits of the workshops in equipping participants with the necessary understanding and confidence to potentially harness PBPK modeling effectively in clinical practice. Please find my comments below for the author’s consideration. While the abstract effectively defines under-served populations, the paper omits a definition of the term “non-modelers”. It would be beneficial for the authors to incorporate a clear explanation of what constitutes a non-modeler in the second section, titled "Demystifying PBPK among non-modelers for wider use in under-served populations." This addition will provide valuable context for the workshop target audience - non-modelers. Page 3 - In the statement, "The workshops appeared to be effective in leveling the ground for attendees to (i) understand the state of science and technology and (ii) confidently apply PBPK," consider adding "PBPK" before "science" in (i) to specify the domain. Additionally, for (ii), consider expanding on the applications, such as applying PBPK in clinical practice, research, and related contexts. It would be helpful for the authors to include a discussion on the challenges encountered during the workshops and any inherent limitations. Drawing from their experiences and insights from organizing these workshops, offering recommendations for effectively organizing similar events worldwide would be invaluable. These recommendations could encompass considerations such as the mode of delivery (online versus in-person), optimal duration, software technologies, and other pertinent factors. This guidance would assist individuals interested in organizing similar workshops in the future. A minor point – the text in the final row and column in the table is missing a closing bracket. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Partly Competing Interests: No competing interests were disclosed. Reviewer Expertise: Clinical Pharmacology, Maternal and Pediatric Pharmacology, PBPK Modeling. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Amaeze OU. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36318 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36318 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Chan E. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r35428 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-35428 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 14 Nov 2023 Eric Chan , National University of Singapore, Singapore, Singapore Approved VIEWS 0 https://doi.org/10.21956/gatesopenres.16225.r35428 The reviewer concurs that an understanding of the concepts of PBPK by healthcare providers is crucial for the successful application of PBPK modeling to optimize pharmacotherapy in specific patient populations. Through the workshops, the authors effectively raised awareness of the ... Continue reading READ ALL The reviewer concurs that an understanding of the concepts of PBPK by healthcare providers is crucial for the successful application of PBPK modeling to optimize pharmacotherapy in specific patient populations. Through the workshops, the authors effectively raised awareness of the relevance of PBPK in optimizing clinical pharmacotherapy. The workshops also help to reduce the barrier clinical practitioners in implementing PBPK modeling to informing drug dosing in children and pregnant women. Similar workshops should be conducted in other parts of the world. Below are comments for the authors to consider. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® ( https://www.simulations-plus.com/software/gastroplus/ ) and PKSim®/Mobi® ( https://www.open-systems-pharmacology.org/) ’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Physiologically based pharmacokinetic modeling I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Chan E. Reviewer Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r35428 ) The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-35428 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 12 Jan 2024 Ping Zhao , Bill & Melinda Gates Foundation, Seattle, USA 12 Jan 2024 Author Response The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance ... Continue reading The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Response: We agree and will add the special population ‘geriatric patients’ to this list, with the notification that this specific population was not included in our workshops. 2. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® (https://www.simulations-plus.com/software/gastroplus/) and PKSim®/Mobi® (https://www.open-systems-pharmacology.org/)’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Response: No, we do not have experience with workshops using other software, we merely suggest that these workshops can also be conducted with other software platforms like PK-Sim and Gastroplus. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. Response : We appreciate that the reviewer addresses this. We had already the discussion internally on how to present the data in the supplementary file as we felt that both were important, i.e., percentages as well as absolute numbers, as the absolute numbers differ between the before and after workshops while percentages are more easier for interpretation. Hence, we decided to present both in the supplementary materials to be as comprehensive as possible and unbiased. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Response: There indeed are limitations and challenges with the workshops as well. We now discuss some limitations and challenges as well, see the addition below. ‘Limitations and challenges of the workshops While the workshops have demonstrated significant value, we acknowledge certain limitations. First, these events have been conducted either in person or online, each possessing its own set of advantages and drawbacks. Online workshops, for instance, are more time-efficient, globally accessible, and cost-effective due to the elimination of travel requirements. However, in-person workshops foster more interactive discussions among delegates, albeit posing challenges in reaching stakeholders on a larger global scale. Second, the workshops have primarily focused on infectious diseases affecting children and pregnant women in low and middle-income countries. While this focus has been beneficial, recent advancements in PBPK offer a broader learning experience. Consequently, discussions regarding the successes and challenges of applying PBPK to support dosing in other underserved populations, such as lactating women and geriatric populations, should be integrated into these workshops.' The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Response: We agree and will add the special population ‘geriatric patients’ to this list, with the notification that this specific population was not included in our workshops. 2. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® (https://www.simulations-plus.com/software/gastroplus/) and PKSim®/Mobi® (https://www.open-systems-pharmacology.org/)’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Response: No, we do not have experience with workshops using other software, we merely suggest that these workshops can also be conducted with other software platforms like PK-Sim and Gastroplus. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. Response : We appreciate that the reviewer addresses this. We had already the discussion internally on how to present the data in the supplementary file as we felt that both were important, i.e., percentages as well as absolute numbers, as the absolute numbers differ between the before and after workshops while percentages are more easier for interpretation. Hence, we decided to present both in the supplementary materials to be as comprehensive as possible and unbiased. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Response: There indeed are limitations and challenges with the workshops as well. We now discuss some limitations and challenges as well, see the addition below. ‘Limitations and challenges of the workshops While the workshops have demonstrated significant value, we acknowledge certain limitations. First, these events have been conducted either in person or online, each possessing its own set of advantages and drawbacks. Online workshops, for instance, are more time-efficient, globally accessible, and cost-effective due to the elimination of travel requirements. However, in-person workshops foster more interactive discussions among delegates, albeit posing challenges in reaching stakeholders on a larger global scale. Second, the workshops have primarily focused on infectious diseases affecting children and pregnant women in low and middle-income countries. While this focus has been beneficial, recent advancements in PBPK offer a broader learning experience. Consequently, discussions regarding the successes and challenges of applying PBPK to support dosing in other underserved populations, such as lactating women and geriatric populations, should be integrated into these workshops.' Competing Interests: NA Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 12 Jan 2024 Ping Zhao , Bill & Melinda Gates Foundation, Seattle, USA 12 Jan 2024 Author Response The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance ... Continue reading The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Response: We agree and will add the special population ‘geriatric patients’ to this list, with the notification that this specific population was not included in our workshops. 2. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® (https://www.simulations-plus.com/software/gastroplus/) and PKSim®/Mobi® (https://www.open-systems-pharmacology.org/)’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Response: No, we do not have experience with workshops using other software, we merely suggest that these workshops can also be conducted with other software platforms like PK-Sim and Gastroplus. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. Response : We appreciate that the reviewer addresses this. We had already the discussion internally on how to present the data in the supplementary file as we felt that both were important, i.e., percentages as well as absolute numbers, as the absolute numbers differ between the before and after workshops while percentages are more easier for interpretation. Hence, we decided to present both in the supplementary materials to be as comprehensive as possible and unbiased. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Response: There indeed are limitations and challenges with the workshops as well. We now discuss some limitations and challenges as well, see the addition below. ‘Limitations and challenges of the workshops While the workshops have demonstrated significant value, we acknowledge certain limitations. First, these events have been conducted either in person or online, each possessing its own set of advantages and drawbacks. Online workshops, for instance, are more time-efficient, globally accessible, and cost-effective due to the elimination of travel requirements. However, in-person workshops foster more interactive discussions among delegates, albeit posing challenges in reaching stakeholders on a larger global scale. Second, the workshops have primarily focused on infectious diseases affecting children and pregnant women in low and middle-income countries. While this focus has been beneficial, recent advancements in PBPK offer a broader learning experience. Consequently, discussions regarding the successes and challenges of applying PBPK to support dosing in other underserved populations, such as lactating women and geriatric populations, should be integrated into these workshops.' The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Response: We agree and will add the special population ‘geriatric patients’ to this list, with the notification that this specific population was not included in our workshops. 2. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® (https://www.simulations-plus.com/software/gastroplus/) and PKSim®/Mobi® (https://www.open-systems-pharmacology.org/)’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Response: No, we do not have experience with workshops using other software, we merely suggest that these workshops can also be conducted with other software platforms like PK-Sim and Gastroplus. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. Response : We appreciate that the reviewer addresses this. We had already the discussion internally on how to present the data in the supplementary file as we felt that both were important, i.e., percentages as well as absolute numbers, as the absolute numbers differ between the before and after workshops while percentages are more easier for interpretation. Hence, we decided to present both in the supplementary materials to be as comprehensive as possible and unbiased. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Response: There indeed are limitations and challenges with the workshops as well. We now discuss some limitations and challenges as well, see the addition below. ‘Limitations and challenges of the workshops While the workshops have demonstrated significant value, we acknowledge certain limitations. First, these events have been conducted either in person or online, each possessing its own set of advantages and drawbacks. Online workshops, for instance, are more time-efficient, globally accessible, and cost-effective due to the elimination of travel requirements. However, in-person workshops foster more interactive discussions among delegates, albeit posing challenges in reaching stakeholders on a larger global scale. Second, the workshops have primarily focused on infectious diseases affecting children and pregnant women in low and middle-income countries. While this focus has been beneficial, recent advancements in PBPK offer a broader learning experience. Consequently, discussions regarding the successes and challenges of applying PBPK to support dosing in other underserved populations, such as lactating women and geriatric populations, should be integrated into these workshops.' Competing Interests: NA Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 26 Oct 2023 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 4 5 6 Version 1 26 Oct 23 read read read read read read Eric Chan , National University of Singapore, Singapore, Singapore Ogochukwu Ukamaka Amaeze , University of Washington, Washington, USA; University of Lagos, Yaba, Nigeria Li Guo-Fu , China Pharmaceutical University,, Nanjing, China; Subei People's Hospital, Yangzhou, China Anil Maharaj , University of British Columbia, Vancouver, Canada Ananth Kumar Kammala , The University of Texas Medical Branch at Galveston, Texas, USA Kristina M. Brooks , University of Colorado Anschutz Medical Campus, Aurora, USA Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Brooks K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 22 Jul 2024 | for Version 1 Kristina M. Brooks , University of Colorado Anschutz Medical Campus, Aurora, USA 0 Views copyright © 2024 Brooks K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Freriksen et al. report on their experiences with providing workshops focused on educating non-modelers on the principles and potential applications of PBPK, with a more specific focus on pediatric, pregnant, and lactating populations. These educational initiatives are important for helping demonstrate the utility of this modeling approach to clinicians and researchers. General feedback from attendees appeared to confirm that these workshops did help “demystify” attendees’ understanding and ability to use/apply PBPK, and general findings from these trainings are helpful as a starting point for figuring out how to educate people on a larger scale. Please consider the following suggestions: Pg. 4, Table 1: consider providing a breakdown of the amount of time spent listening to didactic sessions vs. hands-on learning activities alongside the total duration of the workshops Pg. 4: The statement on “The technological requirement of a proprietary software…” felt a bit out of place and it did feel like some brief commentary on this aspect could also be helpful for readers. I would consider pulling this out into a separate paragraph/subheading on the ability to apply this to other software, but I do think explicitly noting open-source options and some of the pros/cons with this approach would be helpful if the authors are familiar with these other programs. Cost and ability to access software seem like important points to consider in addition to educating non-modelers in this space to ensure that these programs are used after the training. Pg. 5: There is a statement on “We continue to collaborate in this space.” However, I do think some high-level commentary on future directions and ways to potentially increase access would be helpful to give readers a sense of how this educational space will continue to evolve. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Clinical pharmacology, infectious diseases, pediatrics, pregnancy I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Brooks KM. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36314) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36314 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Kammala A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 19 Jul 2024 | for Version 1 Ananth Kumar Kammala , The University of Texas Medical Branch at Galveston, Texas, USA 0 Views copyright © 2024 Kammala A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript, “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in underserved populations,” highlights the success of workshops designed to demystify physiologically based pharmacokinetic (PBPK) modeling for non-modelers. These workshops have effectively raised awareness and understanding among clinicians, pharmacists, and academic researchers about using PBPK to optimize drug dosing in underserved populations. The workshops engaged diverse participants, including PhD students, postdoctoral researchers, pharmacists, and clinical assessors from regulatory agencies. This wide range of attendees indicates the broad relevance and applicability of PBPK modeling in different fields. Although it has several advantages but there are few limitations of the manuscript to be addressed. The workshops relied on the proprietary software Simcyp®, which may not be accessible to all scientists. Although the manuscript suggests similar workshops could be conducted using other PBPK software platforms, such as GastroPlus® and PKSim®, the lack of direct experience with these alternatives is a limitation. The manuscript notes that interpreting survey results, particularly when comparing percentages to absolute numbers, can be challenging. This complexity may introduce bias in understanding the true impact of the workshops. By addressing these strengths and limitations, the manuscript provides a comprehensive overview of the value and challenges of using PBPK modeling to inform drug dosing in underserved populations. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Reproductive pharmacology I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Kammala AK. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36765) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36765 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Maharaj A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 19 Jul 2024 | for Version 1 Anil Maharaj , University of British Columbia, Vancouver, Canada 0 Views copyright © 2024 Maharaj A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The submitted open letter summarizes 5 educational workshops on fostering an understanding of PBPK modeling to non-modelers and provides an analysis of feedback received from attendees. As PBPK modeling is commonly inferred to be an inherently complex process, the submitted letter, which details how educational workshops can be used to bridge the knowledge gap among non-modelers, is of contemporary interest. A key strength of this letter is the collection and analysis of quantitative survey data from workshop attendees as it serves to substantiate assertions/positions discussed by the authors. The following comments are focused on improving the clarity of the submitted letter: 1. Abstract: “As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women.” Logical flaw - The opening sentences of the abstract do not provide an appropriate context/rationale as to why PBPK modeling is suitable for examining PK in underserved populations. 2. “To this end, computational tools such as physiologically based pharmacokinetic (PBPK) modeling which characterize the physiological changes can be used to support dosing decisions (3–5)” References (particularly ref 4 and 5) do not discuss the use of PBPK modeling to support drug dosing decisions. 3. “In parallel, one can compile drug-dependent parameters to construct a drug model, and couple it with the system model through relevant physiological processes concerning the absorption and dis- position of the drug.” Confusing sentence – unclear as to what is the output from combining drug- and system-specific parameters. Consider revising to indicate that combining drug- and system-specific parameters allows models to generate PK estimates that are developmentally specific. 4. Suggest defining the acronym MHRA in the body of the letter. 5. Suggest indicating how many (of the 5) workshops were online and how many were in-person within the body of the letter. 6. Why were MHRA survey results not integrated with the rest of the workshops in supplementary document 2? Were the survey questions for this workshop unique or different? 7. Consider including dialogue on how future workshops could be improved (or separating the ‘Effectiveness of our workshops’ section between strengths and areas for improvement). 8. “The increased confidence and updated perspectives in attendees can be attributed to easy access to PBPK as a technology platform during the workshop, instead of modeling in the form of differential equations.” Do survey results directly support this statement? If so, please include dialogue that links this proposition to quantitative results from the survey. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Pharmacokinetic modeling, pediatrics, pregnancy, and lactation. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Maharaj A. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36766) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36766 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Guo-Fu L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 19 Jul 2024 | for Version 1 Li Guo-Fu , China Pharmaceutical University,, Nanjing, China; Subei People's Hospital, Yangzhou, China 0 Views copyright © 2024 Guo-Fu L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions I find this open letter written by renowned and experienced experts in the field of PBPK modeling to be both interesting and informative. I have one suggestion: should the authors emphasize the best practice strategy in the use of PBPK modeling to address specific medicine use questions in underserved populations? Highlighting the best practice, particularly regarding the differing levels of quantification or verification of PBPK, could enhance the confidence of non-modeler attendees in using their PBPK models to address their intended questions. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Physiologically-based pharmacokinetic modeling; clinical pharmacology; clinical pharmacy; biostatistics I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Guo-Fu L. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36760) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36760 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Amaeze O. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 19 Jul 2024 | for Version 1 Ogochukwu Ukamaka Amaeze , University of Washington, Washington, USA; Clinical Pharmacy and Biopharmacy, University of Lagos, Yaba, Federal Capital Territory, Nigeria 0 Views copyright © 2024 Amaeze O. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The paper “Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations” outlines the details and outcomes of five workshops designed for non-modelers. These workshops aimed to impart knowledge of the science and technology behind PBPK modeling and foster confidence in its application to enhance drug therapy in underserved populations, including children and pregnant women. The paper highlights the benefits of the workshops in equipping participants with the necessary understanding and confidence to potentially harness PBPK modeling effectively in clinical practice. Please find my comments below for the author’s consideration. While the abstract effectively defines under-served populations, the paper omits a definition of the term “non-modelers”. It would be beneficial for the authors to incorporate a clear explanation of what constitutes a non-modeler in the second section, titled "Demystifying PBPK among non-modelers for wider use in under-served populations." This addition will provide valuable context for the workshop target audience - non-modelers. Page 3 - In the statement, "The workshops appeared to be effective in leveling the ground for attendees to (i) understand the state of science and technology and (ii) confidently apply PBPK," consider adding "PBPK" before "science" in (i) to specify the domain. Additionally, for (ii), consider expanding on the applications, such as applying PBPK in clinical practice, research, and related contexts. It would be helpful for the authors to include a discussion on the challenges encountered during the workshops and any inherent limitations. Drawing from their experiences and insights from organizing these workshops, offering recommendations for effectively organizing similar events worldwide would be invaluable. These recommendations could encompass considerations such as the mode of delivery (online versus in-person), optimal duration, software technologies, and other pertinent factors. This guidance would assist individuals interested in organizing similar workshops in the future. A minor point – the text in the final row and column in the table is missing a closing bracket. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Partly Competing Interests No competing interests were disclosed. Reviewer Expertise Clinical Pharmacology, Maternal and Pediatric Pharmacology, PBPK Modeling. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Amaeze OU. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r36318) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-36318 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2023 Chan E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 14 Nov 2023 | for Version 1 Eric Chan , National University of Singapore, Singapore, Singapore 0 Views copyright © 2023 Chan E. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The reviewer concurs that an understanding of the concepts of PBPK by healthcare providers is crucial for the successful application of PBPK modeling to optimize pharmacotherapy in specific patient populations. Through the workshops, the authors effectively raised awareness of the relevance of PBPK in optimizing clinical pharmacotherapy. The workshops also help to reduce the barrier clinical practitioners in implementing PBPK modeling to informing drug dosing in children and pregnant women. Similar workshops should be conducted in other parts of the world. Below are comments for the authors to consider. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® ( https://www.simulations-plus.com/software/gastroplus/ ) and PKSim®/Mobi® ( https://www.open-systems-pharmacology.org/) ’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Is the rationale for the Open Letter provided in sufficient detail? Yes Does the article adequately reference differing views and opinions? Yes Are all factual statements correct, and are statements and arguments made adequately supported by citations? Yes Is the Open Letter written in accessible language? Yes Where applicable, are recommendations and next steps explained clearly for others to follow? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Physiologically based pharmacokinetic modeling I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 12 Jan 2024 Ping Zhao, Bill & Melinda Gates Foundation, Seattle, USA The authors greatly appreciate comments provided by this reviewer. Below are the responses to reviewer's comments: 1. Abstract. It is stated that ‘As such, PBPK has the potential to enhance medicine use for populations that are often under-served globally in drug development and clinical care, namely pediatric patients, pregnant and lactating women’. Perhaps the authors should consider including geriatric patients in this statement even though their focus is on pediatric and obstetric pharmacology subsequently. As geriatric patients are often excluded from clinical trials just like the pediatric patients, pregnant and lactating women, citing them may create the awareness of urgent work needed in the geriatric areas as well. Response: We agree and will add the special population ‘geriatric patients’ to this list, with the notification that this specific population was not included in our workshops. 2. Page 4. It is mentioned that ‘The technological requirement of a proprietary software such as Simcyp and the need to have tutors who are experienced users of the software for our workshops can be replicated using other PBPK software platforms, such as GastroPlus ® (https://www.simulations-plus.com/software/gastroplus/) and PKSim®/Mobi® (https://www.open-systems-pharmacology.org/)’. The reviewer is wondering if such alternative software platforms have been tested before in similar workshops conducted by the authors? If yes, sharing their experiences in this paper briefly may be important as not all scientists have access to the Simcyp software. Response: No, we do not have experience with workshops using other software, we merely suggest that these workshops can also be conducted with other software platforms like PK-Sim and Gastroplus. Using Figure S12 as an example, it is relatively difficult to interpret the bar graph. For example, under ‘no’ as a response, the percentage before workshop was about 10% while the percentage after the workshop was about 20% (2-fold higher). But if we examine the absolute number of responders, they are comparable. The reviewer understands the nuances between percentage versus absolute number, but the interpretation of the results can be biased depending on which read-outs the authors select to present and discuss. Please clarify. Response : We appreciate that the reviewer addresses this. We had already the discussion internally on how to present the data in the supplementary file as we felt that both were important, i.e., percentages as well as absolute numbers, as the absolute numbers differ between the before and after workshops while percentages are more easier for interpretation. Hence, we decided to present both in the supplementary materials to be as comprehensive as possible and unbiased. The paper discusses many benefits of the workshops. Are there any limitations, challenges and considerations? Please discuss. Response: There indeed are limitations and challenges with the workshops as well. We now discuss some limitations and challenges as well, see the addition below. ‘Limitations and challenges of the workshops While the workshops have demonstrated significant value, we acknowledge certain limitations. First, these events have been conducted either in person or online, each possessing its own set of advantages and drawbacks. Online workshops, for instance, are more time-efficient, globally accessible, and cost-effective due to the elimination of travel requirements. However, in-person workshops foster more interactive discussions among delegates, albeit posing challenges in reaching stakeholders on a larger global scale. Second, the workshops have primarily focused on infectious diseases affecting children and pregnant women in low and middle-income countries. While this focus has been beneficial, recent advancements in PBPK offer a broader learning experience. Consequently, discussions regarding the successes and challenges of applying PBPK to support dosing in other underserved populations, such as lactating women and geriatric populations, should be integrated into these workshops.' View more View less Competing Interests NA reply Respond Report a concern Chan E. Peer Review Report For: Demystifying physiologically based pharmacokinetic modelling among non-modelers towards model-informed medicine use in under-served populations. [version 1; peer review: 4 approved, 2 approved with reservations] . Gates Open Res 2023, 7 :128 ( https://doi.org/10.21956/gatesopenres.16225.r35428) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/7-128/v1#referee-response-35428 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with Gates Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Demystifying physiologically based pharmacokinetic...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://gatesopenresearch.org/articles/7-128/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://gatesopenresearch.org/articles/7-128/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://gatesopenresearch.org/articles/7-128/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Freriksen J et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://gatesopenresearch.org/articles/7-128/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://gatesopenresearch.org/articles/7-128", templates : { twitter : "Demystifying physiologically based pharmacokinetic modelling.... Freriksen J et al., published by " + "Gates Open Research" + ", https://gatesopenresearch.org/articles/7-128/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/14896/16225") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "16225"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "35648": 0, "35649": 0, "35650": 0, "35651": 0, "35652": 0, "35653": 0, "35654": 0, "35849": 0, "35850": 0, "35851": 0, "35852": 0, "35853": 0, "35854": 0, "35855": 0, "35856": 0, "35857": 0, "35858": 0, "36309": 0, "36757": 0, "36310": 0, "36758": 0, "36311": 0, "36759": 0, "36312": 0, "36760": 11, "36313": 0, "36761": 0, "36762": 0, "36314": 11, "36315": 0, "36763": 0, "36316": 0, "36764": 0, "36765": 9, "36317": 0, "36766": 5, "36318": 11, "35428": 34, "35429": 0, "35430": 0, "35431": 0, "35645": 0, "35646": 0, "35647": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "6f5a23b6-8af1-45cf-bdaa-e649d0bcac44"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a Gates-funded researcher? If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to Gates Open Research Gates Open Research Browse Gateways How to Publish About Contact Legal For Developers Cookie Notice Privacy Notice RSS Submit via VeriXiv © F1000 Research Limited and its licensors ISSN 2572-4754 var F1000platform = new F1000.Platform({ name: "gates", displayName: "Gates Open Research", hostName: "gatesopenresearch.org", id: "3", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });